NCT02543346View on ClinicalTrials.gov

Comparability and Standardization of Controlled Allergen Challenge Facilities

PHASE4CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

May 31, 2016

Conditions
Allergic Rhinitis
Interventions
DRUG

Cetirizine

Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.

OTHER

Placebo

Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits

Trial Locations (2)

78229

Biogenics Research Chamber, San Antonio

K7L 2V7

Kingston General Hospital, Kingston

Sponsors
All Listed Sponsors
collaborator

Biogenics Research Chamber, LLC

INDUSTRY

lead

Queen's University

OTHER